MAGE-3 (167-176)

MAGE-3 (167-176) is a synthetic peptide fragment derived from the melanoma-associated antigen 3 (MAGE-3) protein, specifically corresponding to amino acid residues 167 through 176 of the full-length sequence. As a member of the cancer-testis antigen family, MAGE-3 is predominantly expressed in various malignant tissues but is absent from most normal somatic cells, making it a valuable target in tumor immunology research. The 167-176 epitope is of particular interest due to its immunogenic properties and its recognized role in antigen presentation pathways, which has positioned it as a key tool for studies focused on cellular immune responses and peptide-MHC binding interactions. Researchers utilize this peptide to dissect the molecular mechanisms underlying tumor antigen recognition, T cell activation, and immune surveillance, contributing to the broader understanding of tumor immunobiology.

Epitope Mapping: The 167-176 fragment of MAGE-3 serves as a defined epitope in studies aiming to map antigenic determinants recognized by cytotoxic T lymphocytes (CTLs). By incorporating this peptide into in vitro assays, researchers can precisely identify T cell receptor (TCR) specificity and delineate the minimal peptide sequence required for effective immune recognition. Such mapping is essential for elucidating the molecular basis of tumor antigenicity and provides a foundation for further exploration of immune escape mechanisms in cancer cells.

Immunogenicity Assessment: In experimental immunology, the peptide is widely used to evaluate the immunogenic potential of tumor-associated antigens. By loading antigen-presenting cells (APCs) with the MAGE-3 (167-176) sequence, investigators can measure the activation and proliferation of antigen-specific T cell populations. These assays facilitate the comparative analysis of peptide immunogenicity, supporting the rational design of immunotherapeutic strategies and the optimization of antigen selection for experimental vaccine platforms.

Peptide-MHC Binding Studies: The defined sequence of this peptide allows for detailed investigation into peptide-major histocompatibility complex (MHC) interactions. Researchers employ the 167-176 epitope to characterize binding affinities and stability within MHC class I molecules, which is critical for understanding the structural requirements of antigen presentation. These insights are fundamental for predicting peptide binding motifs, modeling immune recognition, and advancing computational approaches in immunoinformatics.

T Cell Functional Assays: Functional studies involving the MAGE-3 (167-176) peptide enable the assessment of T cell effector functions in vitro, including cytokine secretion, cytotoxic activity, and proliferation. By stimulating T cells with this defined epitope, scientists can monitor downstream signaling events, characterize functional avidity, and evaluate memory responses. Such assays are instrumental for validating the specificity and potency of engineered T cell receptors or for screening immune-modulating compounds in preclinical research.

Peptide-Based Assay Development: The unique antigenic properties of the MAGE-3 167-176 peptide make it a valuable reference standard in the development and validation of peptide-based immunoassays. It is frequently used as a positive control in enzyme-linked immunospot (ELISpot), flow cytometry, and tetramer staining protocols designed to detect antigen-specific T cells. Its consistent performance in these platforms supports assay reproducibility, quality control, and the benchmarking of novel immunological reagents, thereby enhancing the reliability of experimental readouts in immunological research.

1. Myotropic activity and immunolocalization of selected neuropeptides of the burying beetle Nicrophorus vespilloides (Coleoptera: Silphidae)

2. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

3. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review

4. Zeta-potential-changing nanoparticles conjugated with cell-penetrating peptides for enhanced transfection efficiency

5. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry